MedGenesis Therapeutix Inc.

MedGenesis Therapeutix Inc. is a specialty biopharmaceutical company with a focus on targeted medicines, in particular glial cell line-derived neurotrophic factor (GDNF) protein, leveraging targeted delivery techniques such as convection enhanced delivery (CED) to develop and commercialize innovative treatments for patients with serious central nervous system (CNS) diseases.

© MedGenesis Therapeutix Inc.

What's New

10-Jan-2012: MedGenesis Therapeutix raises $5.0 million in equity financing to support the Phase II development of GDNF in Parkinson's Disease

19-Apr-2011: MedGenesis Therapeutix Selects SynapCell for Key Preclinical Epilepsy Research